Dracunculifoside Q



Compound IDCDAMM02831
Common nameDracunculifoside Q
IUPAC name[3,4-dihydroxy-5-[(3,4,5-trihydroxy-6-pentan-2-yloxyoxan-2-yl)methoxy]oxolan-3-yl]methyl 3-(3,4-dihydroxyphenyl)prop-2-enoate
Molecular formulaC25H36O13

Experimental data

Retention time4.06
Adduct[M+H]+
Actual mz545.219
Theoretical mz545.223
Error6.93
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.7624

Identifiers and class information

Inchi keyJEOODUYTNFLEHG-QCFKNZSENA-N
SmilesO=C(OCC1(O)COC(OCC2OC(OC(C)CCC)C(O)C(O)C2O)C1O)C=CC3=CC=C(O)C(O)=C3
SuperclassLipids and lipid-like molecules
ClassFatty Acyls

Pharmacokinetic properties

Number of descriptor values(#stars)8
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)19
Number of reactive functional groups (#rtvFG)3
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)544.552
Computed dipole moment(dipole)5.647
Total solvent accessible surface area (SASA)915.711
Hydrophobic component of SASA (FOSA)428.755
Hydrophilic component of SASA (FISA)339.548
Pie component of the SASA (PISA)147.408
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1664.27
Number of hydrogen bond donors (donorHB)7
Number of hydrogen bond acceptors (accptHB)17.85
Free energy of solvation of dipole (dip^2/V)0.0191601
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0515737
Globularity descriptor (glob)0.741691
Predicted polarizability in cubic angstroms (QPpolrz)49.658
Predicted hexadecane/gas partition coefficient (QPlogPC16)19.162
Predicted octanol/gas partition coefficient (QPlogPoct)36.784
Predicted water/gas partition coefficient (QPlogPw)28.878
Predicted octanol/water partition coefficient (QPlogPo/w)-0.529
Predicted aqueous solubility (QPlogS)-3.475
Conformation-independent predicted aqueous solubility (CIQPlogS)-3.48
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.415
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)5.97
Predicted brain/blood partition coefficient (QPlogBB)-4.697
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)1.952
Predicted skin permeability, log Kp (QPlogKp)-5.434
PM3 calculated ionization potential (IP(ev))9.051
PM3 calculated electron affinity (EA(eV))0.899
Number of likely metabolic reactions (#metab)7
Prediction of binding to human serum albumin (QPlogKhsa)-1.189
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)215.601
Number of nitrogen and oxygen atoms (#NandO)13
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P02766TTRTransthyretinT86462SEA
P05067APPBeta amyloid A4 proteinT87024SwissTargetPrediction
P17612PRKACAcAMP-dependent protein kinase alpha-catalytic subunitT12808SwissTargetPrediction
P43166CA7Carbonic anhydrase VIIT37541SEA
P23280CA6Carbonic anhydrase VIT06569SEA
P15121AKR1B1Aldose reductaseT26623SwissTargetPrediction
P08253MMP2Matrix metalloproteinase 2T68251SwissTargetPrediction
P45452MMP13Matrix metalloproteinase 13T34296SwissTargetPrediction
Q05655PRKCDProtein kinase C deltaT44861SwissTargetPrediction
P39900MMP12Matrix metalloproteinase 12T03500SwissTargetPrediction
Q9NUW8TDP1Tyrosyl-DNA phosphodiesterase 1T33492SEA
P14679TYRTyrosinaseT97035SEA
Q9GZQ4NMUR2Neuromedin-U receptor 2T04210SEA
O43826SLC37A4Glucose-6-phosphate translocaseT47306SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T86462DI0026Amyloidosis[ICD-11: 5D00]P02766TTR
T87024DI0025Alzheimer disease[ICD-11: 8A20]P05067APP
T87024DI0122Diagnostic imaging[ICD-11: N.A.]P05067APP
T12808DI0279Muscular atrophy[ICD-11: 8B61]P17612PRKACA
T06569DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P23280CA6
T06569DI0372Seborrhoeic dermatitis[ICD-11: EA81]P23280CA6
T26623DI0298Neuropathy[ICD-11: 8C0Z]P15121AKR1B1
T26623DI0366Rheumatoid arthritis[ICD-11: FA20]P15121AKR1B1
T68251DI0238Lung cancer[ICD-11: 2C25]P08253MMP2
T34296DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P45452MMP13
T44861DI0287Myocardial infarction[ICD-11: BA41-BA43]Q05655PRKCD
T03500DI0037Asthma[ICD-11: CA23]P39900MMP12
T03500DI0238Lung cancer[ICD-11: 2C25]P39900MMP12
T03500DI0361Renal cell carcinoma[ICD-11: 2C90]P39900MMP12
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR

Copyright © 2025